

6,8€ Million Granted to nTRACK Horizon 2020 Project Designed to Study Multimodal Nanoparticles for Muscle Regeneration

Grant from European Union's Horizon 2020 programme to nTRACK project designed to study multimodal nanoparticles for structural and functional tracking of stem cell therapy on muscle regeneration

The European Union has awarded a grant of 6,8 million Euro to nTRACK collaborative project. The grant, from the Horizon 2020 framework programme, was awarded to nTRACK, a research and innovation project carried out by an international consortium led by LEITAT. The project partners are: **MJR PharmJet**, Bar Ilan University, Pluristem Therapeutics, University of Mainz, BET Solutions, National Centre for Scientific Research "Demokritos", Vall d'Hebron Research Institute, Vivotecnia Research, RIVM, Asphalion, and Cambridge Nanomaterials Technology. The project will officially be launched on the 16th of October in Barcelona.

The goal of the nTRACK project is to develop a highly sensitive multimodal nano-imaging agent in compliance with current regulatory framework. It will enable non-invasive, quantitative and longitudinal stem cell tracking and whole body bio-distribution. Thereby, it will provide early predictions of cellular therapy treatment outcomes as well as the ability to detect and monitor cell transplants. The nTRACK consortium will utilize stem cells to predict treatment success for muscle regeneration as proof of principle. This predictive model could substantially improve overall management of the disease and will transform cell therapy treatment from "one size fits all" concept towards personalised treatment. **nTRACK** will end up with fully characterized, (nano)safe and functional nano-based imaging agent.

The synthesis of nTRACK NPs and cellular labelling processes will be scaled up and will follow good manufacturing practice (GMP) requirements. In this fascinating project, **MJR PharmJet** will develop a GMP compliant manufacturing setup that enables (semi)continuous production of nano-based imaging agent and will realise the process scale-up.

Contact:

MJR PharmJet GmbH
Nazende Günday Türeli
+ 49 6836 969 11 76

Scientific Coordinator

Marc Masa
mmasa@leitat.org
+34 93 788 23 00

Press:

Max Viallon
mviallon@leitat.org
+34 93 788 23 00



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 760031. This publication reflects only the author's views and the European Union is not liable for any use that may be made of the information contained therein.